Understand your position but personally I'm backing Rebecca , my...

I feel substantially better today , I would have to give that Presentation a solid 8 from 10.

Rebecca spoke well , clear concise strategy it was engaging and educational , couple of gems in there , i'll probably watch it again tomorrow.

I'll definitely increase my position here but like many will want to see the tidal wash of this placement run its course.

The Science is certainly where the value lays , just seems to be really starting to deliver serious data,,, if we weren't already in such a dire financial position this stock would have flown from a Complete Response..

I must admit the data on the retention of Complete Response diagnosis for over 48 months now is worth the $10m MC right now.. no wonder they are now receiving the Main Page of Nature magazine and accolades from industry peers.

Liked the "only real way is up from here" ,, CHM should be circa $100m , I only know of one other Biotech that had successfully completed a Phase I/Ib Human Trial that had an MC under $100m

Full reference list here that I use for scanning 168 Healthcare / Biotechs ,, easily sortable ,, great tool ,,, enjoy ,,NZT
https://www.listcorp.com/asx/sectors/health-care

Understand your position but personally I'm backing Rebecca , my opinion is it's not impossible ,, medium degree of improbable at best but with effort and resources coupled to ability and her resolve ,, I'd say she is going to give it the best crack she can ,,, plus its important to remember here , The Current Financial predicament was generated by the BOD not our Science Staff... NZT

CHM has a Complete Response ,, that leaves the realm of Treatment and enters the ether of Cure......... and that looks to me to be incredibly valuable..